Literature DB >> 24431116

Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).

Beata Kos-Kudła1, Jolanta Blicharz-Dorniak, Daria Handkiewicz-Junak, Barbara Jarząb, Michał Jarząb, Jolanta Kunikowska, Katarzyna Kuśnierz, Robert Król, Leszek Królicki, Maciej Krzakowski, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Waldemar Patkowski, Andrzej W Szawłowski.   

Abstract

An increased interest in gastro-entero-pancreatic neuroendocrine neoplasms (GEP NENs) has recently been observed. These are rare neoplasms and their detection in recent years has improved. Over 50% of GEP NENs are carcinoids, and they are usually found incidentally during surgery in the small intestine and appendix and at diagnosis in distant metastases, mainly to the liver. There is a need for co-operation between specialists in various disciplines of medicine in order to work out the diagnostic and therapeutic guidelines. In this publication, we present general recommendations of the Polish Network of Neuroendocrine Tumours for the management of patients with GEP NENs, developed at the Consensus Conference which took place in Kamień Śląski in April 2013. Members of the guidelines working groups were assigned sections of the 2008 guidance to update. In the subsequent parts of this publication, we present the rules of diagnostic and therapeutic management of: - neuroendocrine neoplasms of the stomach and duodenum (including gastrinoma); - pancreatic neuroendocrine neoplasms; - neuroendocrine neoplasms of the small intestine and the appendix; - colorectal neuroendocrine neoplasms. The proposed recommendations by Polish and foreign experts representing different fields of medicine (endocrinology, gastroenterology, surgery, oncology, nuclear medicine and pathology) will be helpful in the diagnosis and treatment of GEP NENs patients.

Entities:  

Mesh:

Year:  2013        PMID: 24431116     DOI: 10.5603/EP.2013.0028

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  9 in total

1.  Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.

Authors:  Yan Luo; Sanaz Ameli; Ankur Pandey; Pegah Khoshpouri; Mounes Aliyari Ghasabeh; Pallavi Pandey; Zhen Li; Daoyu Hu; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-05-09       Impact factor: 5.315

2.  Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Authors:  Stephan Petersenn; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 3.  Primary small-bowel malignancy: update in tumor biology, markers, and management strategies.

Authors:  Santosh Shenoy
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 4.  Clinical features of gastroenteropancreatic tumours.

Authors:  Paweł Gut; Agata Czarnywojtek; Maciej Bączyk; Katarzyna Ziemnicka; Jakub Fischbach; Elżbieta Wrotkowska; Marek Ruchała
Journal:  Prz Gastroenterol       Date:  2015-06-22

5.  LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis.

Authors:  Ewa Orlewska; Tomasz Bednarczuk; Grzegorz Kaminski; Beata Kos-Kudla
Journal:  Contemp Oncol (Pozn)       Date:  2014-12-31

6.  Role of endoscopic submucosal dissection in treatment of rectal gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Michał Spychalski; Włodzimierz Koptas; Piotr Zelga; Adam Dziki
Journal:  Prz Gastroenterol       Date:  2016-12-16

Review 7.  Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.

Authors:  Beata Kos-Kudła; Jarosław Ćwikła; Marek Ruchała; Alicja Hubalewska-Dydejczyk; Barbara Jarzab; Jolanta Krajewska; Grzegorz Kamiński
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

8.  Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience.

Authors:  Jolanta Kunikowska; Anna Zemczak; Maciej Kołodziej; Paweł Gut; Izabela Łoń; Dariusz Pawlak; Renata Mikołajczak; Grzegorz Kamiński; Marek Ruchała; Beata Kos-Kudła; Leszek Królicki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-24       Impact factor: 9.236

Review 9.  Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study.

Authors:  Beata Kos-Kudła
Journal:  Contemp Oncol (Pozn)       Date:  2015-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.